Semaglutide 910463-68-2 GLP-1 receptor agonism Peptides

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist prescribed for the management of type 2 diabetes and chronic weight management. It works by mimicking the incretin hormones naturally released by the gastrointestinal tract in response to food intake. Semaglutide stimulates glucose-dependent insulin secretion, suppresses glucagon production, and significantly slows gastric emptying, which collectively help lower blood sugar levels and reduce cardiovascular risks. Furthermore, by targeting appetite-control centers in the brain, it effectively induces satiety and curtails food cravings, making it a highly successful therapy for substantial weight loss. It is commonly administered as a weekly subcutaneous injection (under brand names like Ozempic and Wegovy) or as an oral tablet (Rybelsus).